Clinical Trial Update: Clazakizumab for Chronic and Active Antibody Mediated Rejection Post-Kidney Transplant [Phase 1, Phase 2]

View source ↗

Summary

The trial update reports Phase 1/2 results for clazakizumab in chronic and active antibody-mediated rejection after kidney transplantation, with the study statu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Antibody-mediated Rejection
• Kidney Transplant Rejection
• Transplant Glomerulopathy

Drugs mentioned

• Clazakizumab (clazakizumab)

Snippet

Sponsor: Stanley Jordan, MD | Conditions: Antibody-mediated Rejection, Kidney Transplant; Complications | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2025-05-06